We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Samsung Biologics has entered into a partnership agreement with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat cancer.